Literature DB >> 29544764

Appropriateness and yield of surveillance colonoscopy in first-degree relatives of colorectal cancer patients: A 5-year follow-up population-based study.

Franco Armelao1, Riccardo Pertile2, Gianni Miori3, Renzo Franch4, Ivo Avancini3, Alberto Meggio5, Gaia Franceschini3, Cecilia Pravadelli5, Chiara Tieppo3, Katia Faitini3, Davide Giacomin3, Pier Giuseppe Orlandi6, Enrico Tasini5, Giovanni de Pretis3.   

Abstract

BACKGROUND AND AIMS: There are few prospective data about the use of surveillance colonoscopy and the risk of recurrent neoplasia in first degree relatives (FDRs) of colorectal cancer (CRC) patients. We examined the use and yield of surveillance colonoscopy in a population-based screening program (Trentino, Italy)
METHODS: 1252 FDRs have been included in this study. We calculated compliance (percentage of FDRs who underwent surveillance colonoscopy among those eligible), appropriateness of colonoscopy (appropriate if performed within 6 months of the guidelines recommended interval) and diagnostic yield for neoplasia. We compared these data with those of 765 individuals without a family history (FH) of CRC who underwent screening colonoscopy in the same period (controls).
RESULTS: Compliance and appropriateness were higher in FDRs than in controls (93.0% vs. 48.0%; p < 0.001; 59.6% vs. 18.8%; p < 0.0001, respectively). Younger age, female sex, FH of CRC and both non-advanced adenomas (nAA) and advanced adenomas (AA) at screening colonoscopy were predictors of appropriate surveillance. The cumulative incidence of nAA and AA was similar in FDRs and controls (31.7% and 4.9% in FDRs, including three invasive cancers; 32.4% and 5.8% in controls, respectively).
CONCLUSION: FH does not increase the risk of AA in a 5-year follow-up; appropriate surveillance practices in FDRs could be highly expected in an organized screening program.
Copyright © 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Family history of colorectal cancer; Receipt of surveillance colonscopy

Mesh:

Year:  2018        PMID: 29544764     DOI: 10.1016/j.dld.2018.02.007

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  1 in total

1.  Nanocomplexes loaded with miR-128-3p for enhancing chemotherapy effect of colorectal cancer through dual-targeting silence the activity of PI3K/AKT and MEK/ERK pathway.

Authors:  Xin Liu; Chao Dong; Siping Ma; Yongpeng Wang; Tao Lin; Yanxi Li; Shihua Yang; Wanchuan Zhang; Rui Zhang; Guohua Zhao
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.